Quantbot Technologies LP Reduces Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Quantbot Technologies LP decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 65.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,328 shares of the company's stock after selling 8,276 shares during the quarter. Quantbot Technologies LP's holdings in Medpace were worth $1,438,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. Centaurus Financial Inc. lifted its position in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after buying an additional 29 shares in the last quarter. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its stake in shares of Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares during the last quarter. Assetmark Inc. lifted its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Finally, Proficio Capital Partners LLC increased its position in Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MEDP shares. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday. Leerink Partners began coverage on shares of Medpace in a research note on Monday. They issued a "market perform" rating and a $330.00 price objective for the company. Finally, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Medpace currently has an average rating of "Hold" and an average price target of $376.30.

Medpace Stock Down 1.3 %

Shares of NASDAQ MEDP traded down $4.25 during mid-day trading on Friday, reaching $312.36. 343,137 shares of the company were exchanged, compared to its average volume of 298,736. The stock has a market capitalization of $9.52 billion, a PE ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The company's 50 day moving average price is $336.40 and its 200 day moving average price is $339.26.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.